Pharmacoeconomic review report : (Eli Lilly Canada Inc.)Baricitinib (Olumiant)
Baricitinib (Olumiant) is indicated for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying antirheumatic drugs (DMARDs). The recommended dosage is 2 mg tablet daily. At the submitted price of $47.92 per 2 mg tablet, the annual cost is $17,490. The manufacturer submitted a cost-effectiveness analysis based on a discrete-event simulation model. The model compares numerous possible sequences of biologic treatments as current practice for the treatment of RA, including changing to a different treatment, often of a different class, when patients fail their current treatment..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
September 2019 |
|---|---|
| Erschienen: |
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health ; September 2019 |
| Ausgabe: |
Version: final. |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Arthritis, Rheumatoid |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed March 3, 2020) |
|---|
| Umfang: |
1 online resource (1 PDF file (52 pages)) ; illustrations. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1773187783 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1773187783 | ||
| 003 | DE-627 | ||
| 005 | 20230428011936.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211011s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1773187783 | ||
| 035 | |a (DE-599)KEP068712200 | ||
| 035 | |a (NCBI)9917601253406676 | ||
| 035 | |a (EBP)068712200 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Pharmacoeconomic review report |b (Eli Lilly Canada Inc.)Baricitinib (Olumiant) |
| 250 | |a Version: final. | ||
| 264 | 1 | |a Ottawa (ON) |b Canadian Agency for Drugs and Technologies in Health |c September 2019 | |
| 300 | |a 1 online resource (1 PDF file (52 pages)) |b illustrations. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH common drug review | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed March 3, 2020) | ||
| 520 | |a Baricitinib (Olumiant) is indicated for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to one or more disease-modifying antirheumatic drugs (DMARDs). The recommended dosage is 2 mg tablet daily. At the submitted price of $47.92 per 2 mg tablet, the annual cost is $17,490. The manufacturer submitted a cost-effectiveness analysis based on a discrete-event simulation model. The model compares numerous possible sequences of biologic treatments as current practice for the treatment of RA, including changing to a different treatment, often of a different class, when patients fail their current treatment. | ||
| 650 | 2 | |a Arthritis, Rheumatoid |x drug therapy |0 https://id.nlm.nih.gov/mesh/D001172Q000188 | |
| 650 | 2 | |a Azetidines |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D001384Q000627 | |
| 650 | 2 | |a Sulfonamides |x therapeutic use |0 https://id.nlm.nih.gov/mesh/D013449Q000627 | |
| 650 | 2 | |a Treatment Outcome |0 https://id.nlm.nih.gov/mesh/D016896 | |
| 650 | 2 | |a Cost-Benefit Analysis |0 https://id.nlm.nih.gov/mesh/D003362 | |
| 651 | 2 | |a Canada |0 https://id.nlm.nih.gov/mesh/D002170 | |
| 655 | 2 | |a Systematic Review |0 https://id.nlm.nih.gov/mesh/D000078182 | |
| 655 | 2 | |a Tables |0 https://id.nlm.nih.gov/mesh/D020501 | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK549720/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 3994084792 |h h64 NCBI |y zi06404 |z 21-10-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3994011051 |h OLR-NCB-BOOKSHELF |y xsn |z 21-10-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999787325 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3995680801 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 25-10-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3987677465 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-10-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3987767324 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 11-10-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK549720/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK549720/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK549720/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK549720/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK549720/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||